Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy

Completed

Conditions studied: HIV/AIDS

In brief

The purpose of this study is to evaluate cumulative exposure to tenofovir diphosphate (TFV-DP) using dried blood spots (DBS) in treated HIV-infected patients who are receiving a TFV-based regimen. Using DBS will allow the investigators to assess this simple method to measure drug exposure in the clinical setting. The investigators hypothesize that TFV-DP levels will be lowest in individuals with a detectable viral load and highest in those with viral suppression.

Key facts

Study ID

NCT02012621

Run by

University of Colorado, Denver

People needed

807

Starts

2013-12-01

Expected to finish

2017-07-01

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-infected individual.
• 18 years and older.
• Taking tenofovir.
• Blood drawn during regular clinic visit.

You may not qualify if…

• Refusal to participate.
• Pregnancy.
• Inability to provide informed consent.

Where it is running

• University of Colorado-Anschutz Medical Campus — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.